Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Azacitidine
  • Myelodysplastic Syndromes

abstract

  • Decitabine was found to be clinically effective in the treatment of patients with MDS, provided durable responses, and improved time to AML transformation or death. The duration of decitabine therapy may improve these results further.

publication date

  • May 15, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.21792

PubMed ID

  • 16532500

Additional Document Info

start page

  • 1794

end page

  • 803

volume

  • 106

number

  • 8